Arca
Skip to content
Tools
Tools

Diffuse large B-cell lymphoma

Drug research and approvals for diffuse large B-cell lymphoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 298 studies of diffuse large B-cell lymphoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 56 drug trials for it since 2013, FDA has 19 approved and 16 open orphan designations naming it, and the EU has 6 authorised medicines for it.

  • Recruiting worldwide: 298
  • Trials authorized in Canada: 56
  • FDA orphan approvals: 19
  • EU medicines: 6

Recruiting now

Newest posted first, of 298 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 9

Phase 3 12 of 58

Phase 2 12 of 76

Phase 1 or earlier 12 of 57

How its trials ended

1,282 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 353 whose ending is known, 34% met their primary endpoint, 6% missed it and 60% stopped early.

  • Ongoing43534%
  • Completed, result not reported33826%
  • Status unknown15612%
  • Met its primary endpoint1199%
  • Stopped: other or unclear867%
  • Stopped: sponsor or business decision504%
  • Stopped: enrollment or feasibility423%
  • Missed its primary endpoint222%
  • Stopped: lack of efficacy202%
  • Stopped: funding111%
  • Stopped: safety3<1%

Trials authorized in Canada

The 10 newest of 56; search them all in Canada trials
Oct 30, 2026A phase 2/3 multi-arm, open-label study of MK-1045 in combination with zilovertamab vedotin in participants with relapsed/refractory diffuse large B-cell…MK-1045 / Zilovertamab vedotin (MK-2140)Merck & Co. (MSD)Pending
Oct 16, 2026A phase 3, open label, randomized study comparing the efficacy and safety of odronextamab (REGN1979), an ANTI-CD20 × ANTI-CD3 bispecific antibody, in…Odronextamab (REGN1979)RegeneronPending
Jun 20, 2025An open-label, multicenter, phase 1 trial to evaluate the safety, pharmakonetics, and anti-tumour activity of TLN-121 as a single agent and in combination with…TLN-121 / Cyclophosphamide / Lunsumio (mosunetuzumab) / Columvi (glofitamab) /…Treeline BiosciencesOngoing
Dec 13, 2024A randomized, open-label, multicenter, phase 3 study of zilovertamab vedotin (MK-2140) in combination with r-chp versus r-chop in participants with previously…Zilovertamab vedotin (MK-2140) / Rituximab / Cyclophosphamide / Doxorubicin /…Merck & Co. (MSD)Ongoing
Jul 10, 2024A prospective, multicenter, phase II trial to evaluate the efficacy of zanubrutinib and tislelizumab as well as standard of care for the treatment of patients…Zanubrutinib (BGB3111) / Tislelizumab (BGB-A317)Dr. John Kuruvilla, University Health NetworkOngoing
Apr 30, 2024A phase 3, multicenter, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of golcadomide plus r-chop chemotherapy vs placebo…Golcadomide (BMS-986369, CC-99282)/ Rituximab/ Cyclophosphamide/ Doxorubicin/…Bristol-Myers SquibbOngoing
Feb 23, 2024Feasibility trial of glofitamab in a response adapted approach incorporating interim fdg pet and ctdna to optimize primary therapy of DLBCL (GRAIL)Columvi / Actemra / Avtozma / TyenneDr. John Kuruvilla, University Health NetworkOngoing
Nov 7, 2023Optimizing lymphodepletion to improve outcomes in patients receiving ANTI-CD19 car t cell therapy with kymriah/tisagenlecleucel (LOKI)Fludarabine / CyclophosphasmideUniversity Health NetworkClosed
Jul 19, 2023A multi-center single arm phase II study to evaluate the safety and efficacy of genetically engineered autologous cells expressing ANTI-CD20 and ANTI-CD19…MB-CART2019.1 (zamtocabtagene autoleucel)Miltenyi Biomedicine, GmbHOngoing
Jul 6, 2023A phase III, multicenter, randomized, open label study comparing the efficacy and safety of glofitamab (RO7082859) in combination with polatuzumab vedotin plus…Columvi / Polivy / Actemra (foreign-market source) / RituxanRocheOngoing

FDA orphan designations

Approved first, then open designations, newest first; 15 of 35
Feb 5, 2026YescartaTreatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12…Kite Pharma, Inc.Approved
Apr 19, 2023PolivyIn combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have…Genentech, Inc.Approved
Jun 24, 2022BreyanziTreatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified…Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyApproved
Jun 24, 2022BreyanziTreatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified…Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyApproved
Jun 24, 2022BreyanziTreatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified…Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyApproved
Apr 1, 2022YescartaTreatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12…Kite Pharma, Inc.Approved
Dec 2, 2021RituxanTreatment of pediatric patients aged 6 months and older with previously untreated, advanced stage, CD20-positive diffuse large B-cell…Genentech, Inc.Approved
Apr 23, 2021ZynlontaTreatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including…ADC Therapeutics SAApproved
Feb 5, 2021BreyanziTreatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including…Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyApproved
Feb 5, 2021BreyanziTreatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including…Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyApproved
Feb 5, 2021BreyanziTreatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including…Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyApproved
Jul 31, 2020MonjuviMONJUVI® is indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell…Incyte CorporationApproved
Jun 22, 2020XpovioXPOVIO is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise…Karyopharm Therapeutics, Inc.Approved
Jun 10, 2019PolivyPOLIVY in combination with bendamustine and a rituximab product is indicated for the treatment of adult patients with relapsed or…Genentech, Inc.Approved
May 1, 2018KymriahKYMRIAH is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of Adult patients with relapsed…Novartis Pharmaceuticals CorporationApproved

Medicines authorised in the EU

Newest first
Sep 22, 2023TepkinlyEpcoritamabAbbVie Deutschland GmbH & Co. KGEMA ↗
Jul 7, 2023ColumviGlofitamabRoche Registration GmbHEMA ↗
Dec 20, 2022ZynlontaLoncastuximab tesirineSwedish Orphan Biovitrum ABEMA ↗
Apr 4, 2022BreyanziLisocabtagene maraleucelBristol-Myers Squibb Pharma EEIGEMA ↗
Aug 26, 2021MinjuviTafasitamab · orphanIncyte Biosciences Distribution B.V.EMA ↗
Jan 16, 2020PolivyPolatuzumab vedotin · orphanRoche Registration GmbHEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.